Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Shakti D. Shukla, Steven L. Taylor, Peter G. Gibson, Daniel Barker, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Alan L. James, Geraint B. Rogers, Jodie L. Simpson

Research output: Contribution to journalArticlepeer-review

Abstract

Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

Original languageEnglish
Number of pages4
JournalThorax
Early online date7 Jan 2021
DOIs
Publication statusE-pub ahead of print - 7 Jan 2021

Keywords

  • asthma
  • asthma pharmacology
  • cytokine biology
  • respiratory infection

Fingerprint Dive into the research topics of 'Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy'. Together they form a unique fingerprint.

Cite this